What is the recommended treatment for agitation in a patient with traumatic brain injury?

Treatment for TBI with Agitation

For agitation in traumatic brain injury patients, use beta-blockers (propranolol or pindolol) as first-line scheduled therapy, with atypical antipsychotics (particularly olanzapine) reserved for as-needed acute management, while avoiding benzodiazepines and haloperidol. 1

Pharmacological Management Strategy

First-Line Scheduled Treatment

Beta-blockers provide the strongest evidence for managing post-TBI agitation and should be initiated early. Propranolol and pindolol have demonstrated efficacy in reducing agitation intensity, though evidence for frequency reduction is mixed 1, 2. The rationale is compelling: TBI creates a hyperadrenergic state with elevated norepinephrine levels that exacerbate cerebral metabolic crisis, and beta-blockade addresses this underlying pathophysiology 3.

Key considerations for beta-blockers:

• Monitor for hypotension and bradycardia, which can worsen TBI outcomes
• Despite theoretical concerns, meta-analysis shows mortality benefit (OR 0.39) with in-hospital beta-blocker use after TBI 3
• Start at low doses and titrate carefully

Second-Line Scheduled Options

Antiepileptic mood stabilizers (valproic acid, carbamazepine) represent reasonable alternatives when beta-blockers are contraindicated:

• Valproic acid shows promise in recent evidence, with one 2026 study demonstrating 85.7% agitation relief, achieving control by day 3 (median) versus 4-5 days for alternatives 4
• Better tolerated than carbamazepine; monitor liver enzymes 5
• Carbamazepine has grade C evidence but requires CBC and liver monitoring due to problematic side effects 2

Amantadine can be considered but evidence remains unclear 1

Acute/PRN Management

For immediate agitation crises requiring rapid control:

Atypical antipsychotics (olanzapine preferred) over typical antipsychotics:

• Use shortest duration possible 2
• Olanzapine has most compelling evidence among atypicals 1, 6
• Avoid haloperidol due to extrapyramidal symptoms and lack of superiority 1

Combination therapy (benzodiazepine + antipsychotic) is suggested by some emergency guidelines 7, but this applies to general agitation, not TBI-specific populations where benzodiazepines should be avoided.

Medications to AVOID

Benzodiazepines should be avoided in TBI patients despite their use in general agitation protocols 1. They cause:

• Tolerance and addiction
• Cognitive impairment (particularly problematic in TBI)
• Paradoxical agitation in ~10% of patients 5
• Depression and respiratory concerns

Haloperidol should be avoided as first-line despite emergency department guidelines recommending it for undifferentiated agitation 1. The TBI population requires different considerations than general psychiatric agitation.

Non-Pharmacological Interventions

Always implement before or alongside medications:

• Environmental modifications: Reduce sensory stimulation, safety-proof rooms, eliminate triggers 8
• Family presence and orientation: Critical during acute recovery 6
• Treat underlying causes: Pain, infection, drug adverse effects must be addressed first 2
• Avoid physical restraints when possible 2

Critical Pitfalls

1. Don't use vital signs alone to assess agitation severity - they lack validity and specificity for pain/agitation in TBI 9
2. Don't assume psychiatric agitation protocols apply - TBI patients have unique pathophysiology requiring different approaches
3. Don't continue ineffective medications - if no response after appropriate trial, taper and discontinue
4. Don't forget the hyperadrenergic state - this is why beta-blockers have mechanistic rationale beyond empiric use

Emerging Evidence

Dexmedetomidine shows potential benefit in acute settings according to 2026 systematic review, with three new studies suggesting efficacy 10. However, this is primarily for ICU/acute sedation rather than rehabilitation-phase agitation management.

Evidence Quality Note

The evidence base remains frustratingly limited - most studies are observational with small sample sizes 10, 1, 2. The 2016 French guidelines noted most data are old and yield only grade B-C recommendations 2. The 2026 systematic review concluded there remain "insufficient data to recommend the use of any medications" definitively 10, yet clinical reality demands treatment decisions. In this context of equipoise, the beta-blocker approach has the strongest mechanistic rationale, addresses the underlying TBI pathophysiology, and carries a mortality benefit 3.